XIAP and breast carcinoma: Our in vitro and in vivo preclinical studies identify the cellular stress-mediated induction of the XIAP-NFκB signaling axis as a novel mechanism of immune evasion and reveal the potential of targeting this signaling pathway to improve breast cancer immunotherapy.